HIV cases continue to climb with a total of 33.3 Million victims across the world. The report analyses the overall market size, and country level developments. It also provides the future landscape of global HIV therapeutics market which looks promising with the commercialisation of new and innovative drugs. A brief description and recent activities of key market players have been included to show private sectors' participation. Overall, the report is likely to provide intending clients with an effective insight into the global HIV therapeutics market.
Highly Active Antiretroviral Therapy (HAART) has been effective in reducing the number of HIV particles in the bloodstream, leading to a reduction in AIDS-related mortality. The market for this type of therapy has also expanded over time hitting around US$ 12.6 Billion in 2010. Among all the key drugs in the market, multi-class combination product, Atripla dominates the HIV therapeutics market as products from other classes, such as NRTIs, NNRTIs, PIs, and Fusion Inhibitors are following the sales pattern. A number of key HIV compounds are also in various phases of clinical trials being developed by companies like Gilead Sciences, Tibotec, etc. The HIV therapeutics market is attracting a huge amount of investment with majority of contribution coming from the public sector.
The report “Global HIV Therapeutics Market Analysis” is available from Piribo at:
Piribo product ID: RCS00820
# # #
Piribo http:www.piribo.com is the source for information products concerning the global biotechnology and pharmaceutical industries. Here you can browse and buy thousands of business information studies, market reports and books.